These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 29069007

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Severe immune thrombocytopenia in pregnancy treated with Eltrombopag - A case report.
    Ferreira IJMCF, Sousa F, Vasco EM, Areia ALFA, Moura JPAS, Carda J, Ribeiro L.
    J Gynecol Obstet Hum Reprod; 2018 Oct; 47(8):405-408. PubMed ID: 29981476
    [Abstract] [Full Text] [Related]

  • 8. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
    Modi Y, Shaaban H, Gauchan D, Maroules M.
    J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
    Kowalczyk M, Rubinstein PG, Aboulafia DM.
    J Int Assoc Provid AIDS Care; 2015 Feb; 14(3):211-6. PubMed ID: 25504472
    [Abstract] [Full Text] [Related]

  • 11. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
    Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.
    Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Is there a role for low-dose eltrombopag as maintenance therapy in the treatment of immune thrombocytopenia?
    Vlachaki E, Sousos N, Perifanis V, Kaiafa G, Onoufriadis I, Hatzitolios A, Boura P.
    Acta Haematol; 2015 Nov; 133(1):78-82. PubMed ID: 25170628
    [Abstract] [Full Text] [Related]

  • 18. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M.
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
    Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB.
    Blood; 2017 Dec 07; 130(23):2527-2536. PubMed ID: 29042367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.